RA Pharmaceuticals IPO Research Information

RA Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on RA Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
RA Pharmaceuticals	RARX - NASDAQ	$12.00-$14.00	$13.00	$14.16	7.05 million	10/26/2016
Underwriter(s): Credit Suisse, Jefferies, BMO Capital Markets
Co-Manager(s): SunTrust Robinson Humphrey
Industry: Health Care
Filing(s): Filed 2016-09-30 Terms Added 2016-10-17

RA Pharmaceuticals Quote & Chart - Click for current quote - RARX

About RA Pharmaceuticals (adapted from RA Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company using our proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "RARX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.